{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/XVIPF"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"XVIPF","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"XVIPF\",,,,,undefined,":{"symbol":"XVIPF","market":"US","secType":"STK","nameCN":"Xvivo Perfusion AB","latestPrice":32.9,"timestamp":1748376000000,"preClose":32.9,"halted":0,"volume":0,"delay":15,"floatShares":24995755,"shares":31499470,"eps":0.370344,"marketStatus":"Closed","change":0,"latestTime":"05-27 16:00:00 EDT Delay","open":32.9,"high":32.9,"low":32.9,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":0.370344,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1748419200000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"PINK LIMITED","adjPreClose":32.9,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"XVIPF\",,,,,undefined,":{"symbol":"XVIPF","floatShares":24995755,"roa":"2.66%","roe":"6.69%","lyrEps":0.305001,"shares":31499470,"dividePrice":0,"high":32.9,"amplitude":0,"preClose":32.9,"low":32.9,"week52Low":25.81,"pbRate":"4.76","psRate":"11.66","week52High":52.3768,"institutionHeld":0,"latestPrice":32.9,"eps":0.370344,"divideRate":0,"volume":0,"delay":15,"ttmEps":0.370344,"open":32.9,"prevYearClose":41.1,"prevWeekClose":32.9,"prevMonthClose":33.45,"prevQuarterClose":30,"fiveDayClose":32.9,"twentyDayClose":33.45,"sixtyDayClose":40.99},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/XVIPF\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"XVIPF\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2532042400","title":"Exploring 3 Top Undervalued European Small Caps With Recent Insider Action","url":"https://stock-news.laohu8.com/highlight/detail?id=2532042400","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532042400?lang=en_us&edition=fundamental","pubTime":"2025-05-01 13:39","pubTimestamp":1746077968,"startTime":"0","endTime":"0","summary":"The European market has recently seen positive momentum, with the pan-European STOXX Europe 600 Index climbing 2.77% amid easing trade tensions and a more optimistic economic outlook. Despite some concerns about potential slowdowns in business activity, the region's diversified trading relationships have helped maintain stability. In this environment, identifying small-cap stocks that are potentially undervalued can be appealing to investors looking for growth opportunities. These companies often benefit from nimble operations and unique market positions, which could be advantageous as broader economic conditions evolve.Top 10 Undervalued Small Caps With Insider Buying In Europe. Click here to see the full list of 70 stocks from our Undervalued European Small Caps With Insider Buying screener.Unlock comprehensive insights into our analysis of Alimak Group stock in this valuation report.Examine Alimak Group's past performance report to understand how it has performed in the past.Overvie","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exploring-3-top-undervalued-european-053928770.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4198","XVIPF","XVIPY"],"gpt_icon":0},{"id":"2531226470","title":"XVIVO Presents 12-Month Follow-Up Results from European Multicenter Heart Transplantation Trial at ISHLT in Boston","url":"https://stock-news.laohu8.com/highlight/detail?id=2531226470","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531226470?lang=en_us&edition=fundamental","pubTime":"2025-04-29 14:20","pubTimestamp":1745907600,"startTime":"0","endTime":"0","summary":"GOTHENBURG, SE / ACCESS Newswire / April 29, 2025 / XVIVO Perfusion AB  - The 12-month follow-up results from XVIVO's European multicenter heart trial, NIHP2019, was presented at the 2025 International Society for Heart and Lung Transplantation  Annual Meeting in Boston, USA. The trial focused on heart transplantation outcomes using XVIVO Heart Assist Transport.\"This is the first randomized controlled trial of a donor heart perfusion device to demonstrate superiority over preservation on ice. Now we can see that the 76 percent risk reduction for severe PGD previously reported is also translated into higher 12-month survival rates. This makes us very proud, as it brings us one step closer to realizing our vision that 'nobody should die waiting for a new organ'. Our heart technology demonstrates XVIVO's dedication as a research-driven and innovative company committed to changing the paradigm of heart preservation,\" says Christoffer Rosenblad, CEO of XVIVO.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/xvivo-presents-12-month-results-062000481.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4198","XVIPY","HOPE","XVIPF","BK4211"],"gpt_icon":0},{"id":"2529886642","title":"Interim Report January-March 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2529886642","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529886642?lang=en_us&edition=fundamental","pubTime":"2025-04-24 13:50","pubTimestamp":1745473800,"startTime":"0","endTime":"0","summary":"GOTHENBURG, SE / ACCESS Newswire / April 24, 2025 / XVIVO Perfusion AB . Net sales increased to SEK 218.6 million , corresponding to growth of 18 percent in SEK and 16 percent in local currencies. Organic growth amounted to 14 percent in local currencies.The Business areas Thoracic and Abdominal delivered sales growth in local currencies: Thoracic 16 percent and Abdominal 28 percent. Services delivered negative growth of -6 percent.Total gross margin was 73 percent . The gross margin for the business areas amounted to: Thoracic 82 percent , Abdominal 63 percent  and Services 38 percent .Operating income  increased to SEK 26.6 million . Adjusted EBIT increased by 50 percent to SEK 29.8 million .Operating income before depreciation and amortization  increased to SEK 43.0 million , corresponding to an EBITDA margin of 20 percent . Adjusted EBITDA increased to SEK 46.2 million , corresponding to an adjusted EBITDA margin of 21 percent .FDA approval for continued use of XVIVO's heart techno","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/interim-report-january-march-2025-055000515.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4198","XVIPF","EBIT","XVIPY"],"gpt_icon":0},{"id":"2527029429","title":"Conference Call on Interim Report January-March 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2527029429","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527029429?lang=en_us&edition=fundamental","pubTime":"2025-04-16 02:30","pubTimestamp":1744741800,"startTime":"0","endTime":"0","summary":"GOTHENBURG, SE / ACCESS Newswire / April 15, 2025 / XVIVO Perfusion AB  - Invitation to attend XVIVO's conference call regarding the interim report January-March 2025. The presentation will be held in English.Time: Thursday, April 24 at 2.00 pm CET / 8.00 am EST. A press release containing XVIVO's interim report January-March 2025 will be released on April 24, 2025 at 7.30 am CET / 1.30 am EST.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/conference-call-interim-report-january-183000477.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4198","XVIPY","XVIPF"],"gpt_icon":0}],"pageSize":4,"totalPage":4,"pageCount":1,"totalSize":15,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/XVIPF\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-04-24","symbol":"XVIPF","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1713931200000,"reportTimeType":"","actualEps":null},{"date":"2022-10-27","symbol":"XVIPF","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1666857600000,"name":null,"time":"","dateTimestamp":1666843200000,"actualEps":null},{"date":"2022-07-13","symbol":"XVIPF","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1657699200000,"name":null,"time":"","dateTimestamp":1657684800000,"actualEps":null},{"market":"US","date":"2022-04-25","symbol":"XVIPF","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1650859200000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"XVIPF\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"XVIPF\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2,"buy":0.4,"hold":0.4,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.4,"analysts":5,"updateTime":1745726400000}}}